Diatrizoate MegluminePronunciation: DYE-a-trye-ZOE-ate ME-gloo-meen
Class: Radiopaque agent
- Injection, intravesical 180 mg/mL
- Injection, intravesical 300 mg/mL
Provides contrast enhancement of the bladder.
Indications and Usage
A diagnostic agent for retrograde cystourethrography.
Hypersensitivity to salts of diatrizoic acid.
Dosage and AdministrationAdults
Intravesical 25 to 300 mL instilled into the bladder depending on the age of the patient and degree of bladder irritability. Amounts greater than 300 mL may be used if bladder capacity allows.
- For instillation into the bladder; not for intravascular injection.
- A laxative the night before the examination and a low-residue diet the day before the procedure is recommended.
- After catheterization, fill the bladder to capacity without excessive pressure.
- Diatrizoate 30% may be diluted with sterile water or sterile saline.
Store between 68° and 77°F. Protect from light.
None well documented.
Laboratory Test Interactions
Diatrizoate may interfere with some chemical determinations made on urine specimens. Therefore, collect urine before diatrizoate administration or 2 or more days afterward.
Anuria, hematuria, oliguria, perforation of the urethra or bladder, urinary tract infection.
Hypersensitivity or anaphylactoid reactions (eg, convulsions or shock, edema of the face, glottis, respiratory distress).
Category C .
Diatrizoate is classified as compatible by the American Academy of Pediatrics.
No information available per prescribing information.
Severe sensitivity reactions may occur if intravasation occurs. Diatrizoate solution also contains iodine; therefore, use with extreme caution in patients with a history of hypersensitivity to iodine.
During administration, avoid excessive pressure, rapid or acute distention of the bladder, and/or trauma.
Urinary tract infection
Use with caution in patients with a known active infection of the urinary tract.
- Advise patients to inform health care provider if they may be pregnant or are breast-feeding.
- Instruct patients to inform health care provider if they have ever had an allergic or hypersensitivity reaction to previous injections of dyes or contrast agents.
Copyright © 2009 Wolters Kluwer Health.
More Diatrizoate Meglumine resources
- Cystografin Prescribing Information (FDA)
- Gastrografin Prescribing Information (FDA)
- Hypaque Prescribing Information (FDA)
- Hypaque-76 Prescribing Information (FDA)
- Reno-30 Prescribing Information (FDA)
- Reno-60 Prescribing Information (FDA)
- Reno-Dip Prescribing Information (FDA)
- RenoCal-76 Prescribing Information (FDA)
- Renografin-60 Prescribing Information (FDA)